Quality of life (QoL) assessment of insulin detemir and NPH human insulin in Japanese subjects with diabetes on basal-bolus regimen

被引：0
|
作者：
Ishii, Hitoshi
Iwamoto, Yasuhiko
Kaku, Kohei
Kawamori, Ryuzo
Tajima, Naoko
Kobayashi, Masashi
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A710 / A710
页数：1
相关论文
共 50 条
  • [41] BASAL-BOLUS REGIMEN WITH INSULIN ANALOGUES VERSUS HUMAN INSULIN IN MEDICAL PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CONTROLLED TRIAL IN LATIN AMERICA
    Bueno, Elvio
    Benitez, Aldo
    Vera Rufinelli, Jazmin
    Figueredo, Rafael
    Alsina, Shirley
    Ojeda, Aldo
    Samudio, Sandra
    Caceres, Mirta
    Arguello, Rocio
    Romero, Fabiola
    Echague, Gloria
    Pasquel, Francisco
    Umpierrez, Guillermo E.
    ENDOCRINE PRACTICE, 2015, 21 (07) : 807 - 813
  • [42] Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index
    Rašlová K.
    Tamer S.C.
    Clauson P.
    Karl D.
    Clinical Drug Investigation, 2007, 27 (4) : 279 - 285
  • [43] Less weight gain and hypoglycaemia with once-daily insulin detemir than with NPH insulin in basal-bolus therapy of overweight type 2 diabetes patients: The PREDICTIVE-BMT trial
    Montanana, C. Fajardo
    Herrero, C. Hernandez
    Fernandez, M. Rivas
    DIABETOLOGIA, 2007, 50 : S404 - S404
  • [44] Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin
    De Leeuw, I
    Vague, P
    Selam, JL
    Skeie, S
    Lang, H
    Draeger, E
    Elte, JWF
    DIABETES OBESITY & METABOLISM, 2005, 7 (01): : 73 - 82
  • [45] Effects of QD insulin detemir or neutral protamine hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen
    Russell-Jones, D
    Simpson, R
    Hylleberg, B
    Draeger, E
    Bolinder, J
    CLINICAL THERAPEUTICS, 2004, 26 (05) : 724 - 736
  • [46] Compared to NPH insulin, insulin detemir is associated with a superior efficacy: tolerability profile and reduced excess weight gain when used in basal-bolus therapy for children and adolescents with type 1 diabetes
    Robertson, Kenneth
    Gall, Mari Anne
    HORMONE RESEARCH, 2006, 65 : 57 - 57
  • [47] Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index
    Raslova, Katarina
    Tamer, Soren Can
    Clauson, Per
    Karl, Diane
    CLINICAL DRUG INVESTIGATION, 2007, 27 (04) : 279 - 285
  • [48] Italian experience trial for the implementation of insulin glargine in basal-bolus regimen in patients with type 1 diabetes
    Brunetti, P.
    Muggeo, M.
    Cattin, L.
    Arcangeli, A.
    Pozzilli, P.
    Provenzano, V.
    Francesconi, A.
    Calatola, P.
    Santeusanio, F.
    DIABETOLOGIA, 2007, 50 : S394 - S394
  • [49] Basal-Bolus Insulin Regimen for Hospitalised Patients with COVID-19 and Diabetes Mellitus: A Practical Approach
    Attri, Bhawna
    Goyal, Alpesh
    Gupta, Yashdeep
    Tandon, Nikhil
    DIABETES THERAPY, 2020, 11 (09) : 2177 - 2194
  • [50] Efficacy and safety of insulin glulisine versus insulin lispro as part of a basal-bolus insulin regimen in children and adolescents with type I diabetes mellitus
    Philotheou, A.
    Arslanian, S.
    Blatniczky, L.
    Peterkova, V.
    Souhami, E.
    Danne, T.
    DIABETOLOGIA, 2008, 51 : S382 - S382
12345